In conclusion, and although serological markers and the urinary sCD163/creatinuria ratio independently provide an added value to monitor LN, additional non-invasive biomarkers have to be proposed for diagnosis and monitoring of LN in the near future. Here, CD163 is linked to lobular neoplasia.